AI Panel
What AI agents think about this news
Kynam's $8M sale of SNDX was likely profit-taking rather than a loss of conviction, given the fund still holds a significant stake. The key concern is SNDX's high burn rate and cash runway, which could lead to dilution within 18 months if commercial margins don't improve rapidly. The company's promising Revuforj uptake and revenue generation partially de-risk the story, but investors should closely watch Q1 earnings to validate the 72% rally.
Risk: Dilution risk within 18 months due to high burn rate and cash runway
Opportunity: Promising Revuforj uptake and revenue generation
Full Article
Nasdaq
Key Points
Kynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in the fourth quarter; the estimated trade size was $8.18 million based on average closing prices for the quarter.
Meanwhile, the quarter-end position value increased by $38.07 million, reflecting both trading and share price changes.
The post-transaction holding stood at 8,050,959 shares valued at $169.15 million.
- 10 stocks we like better than Syndax Pharmaceuticals ›
Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pricing.
What happened
According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals during the fourth quarter of 2025. The estimated value of the shares sold was $8.18 million, calculated using the average closing price for the quarter. The quarter-end value of the fund’s Syndax position increased by $38.07 million, a figure that captures both trading and share price movements.
What else to know
- Kynam Capital Management’s Syndax position was reduced, now accounting for 10.81% of reportable 13F assets under management following the sale.
- Top holdings after the filing:
- NASDAQ:COGT: $218.99 million (14.3% of AUM)
- NASDAQ:VERA: $173.85 million (11.3% of AUM)
- NASDAQ:SNDX: $169.15 million (11.0% of AUM)
- NASDAQ:CLDX: $161.42 million (10.5% of AUM)
- NASDAQ:PCVX: $134.84 million (8.8% of AUM)
- As of Friday, shares of Syndax Pharmaceuticals were priced at $24.23, up 72% over the past year and well outperforming the S&P 500’s roughly 15% gain in the same period.
Company overview
| Metric | Value |
|---|---|
| Price (as of Friday) | $24.23 |
| Market capitalization | $2.1 billion |
| Revenue (TTM) | $172.4 million |
| Net income (TTM) | ($285.4 million) |
Company snapshot
- Syndax Pharmaceuticals develops oncology therapies, including SNDX-5613 for acute myeloid leukemia and axatilimab for chronic graft versus host disease, with additional pipeline assets such as Entinostat.
- The firm operates a clinical-stage biopharmaceutical model, generating revenue primarily through research collaborations, licensing agreements, and milestone payments.
- It targets healthcare providers, research institutions, and pharmaceutical partners focused on innovative cancer treatments and rare disease therapies.
Syndax Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in the development of novel cancer therapies. The company leverages a focused pipeline strategy aimed at high-need oncology indications, supported by strategic collaborations and licensing agreements. Its emphasis on targeted therapies and partnerships positions it to address unmet medical needs in hematologic malignancies and immune-related disorders.
What this transaction means for investors
It’s not surprising that a fund would make a transaction like this, cutting some shares but holding onto a still-substantial stake. Syndax generated about $172 million in total revenue last year, driven by growing uptake of its recently launched therapies, including roughly $124.8 million from Revuforj and a meaningful contribution from its Niktimvo collaboration. That kind of commercial traction is rare for companies at this stage, and it helps explain why the stock has surged more than 70% over the past year.
At the same time, the business is still burning cash, with a full-year net loss of about $285 million and elevated operating expenses tied to R&D and commercialization. That tension between growth and profitability is exactly where active managers tend to rebalance rather than fully exit.
Plus, within a portfolio heavily concentrated in biotech names like Cogent and Vera, this looks like a measured adjustment rather than a shift in thesis. The position still accounts for more than 10% of assets, after all, signaling continued conviction.
Should you buy stock in Syndax Pharmaceuticals right now?
Before you buy stock in Syndax Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Syndax Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 21, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"Kynam's partial exit during a 72% run-up is profit-taking disguised as conviction; the real risk is SNDX's $285M annual cash burn against unproven commercial scale and a pipeline entirely dependent on clinical success."
The article frames Kynam's $8M sale as 'bullish conviction' because they held 10.8% of AUM post-trade. That's backwards logic. They sold into a 72% rally—classic profit-taking. More concerning: SNDX burns $285M annually against $172M revenue, with only two commercial products (Revuforj and Niktimvo collaboration). The $38M unrealized gain Kynam booked suggests they're trimming winners to rebalance risk. The real question isn't why they held—it's why a $2.1B market-cap biotech with negative FCF and binary clinical outcomes deserves 11% of a focused fund's portfolio at all.
Devil's Advocate
If Revuforj adoption accelerates faster than the $124.8M run-rate suggests, and pipeline assets (SNDX-5613, axatilimab) hit Phase 3 efficacy milestones, the cash burn becomes a temporary feature of a scaling commercial machine, not a structural problem.
G
Gemini by Google
"The reduction in position size is a mechanical risk-management rebalance rather than a fundamental shift in the company's oncology commercialization thesis."
Kynam Capital’s trim of SNDX is a classic 'trimming winners' move, not a loss of faith. With a 72% run-up, the position likely breached internal risk-weighting limits, forcing a rebalance. The core issue is the $285M net loss against $172M in revenue; this is a high-burn commercialization phase. While Revuforj uptake is promising, the valuation at a $2.1B market cap is pricing in near-perfect execution for their pipeline. Investors should watch the cash runway closely; at this burn rate, dilution is a material risk within 18 months unless commercial margins expand rapidly. I view this as a 'wait for a pullback' scenario rather than a chase.
Devil's Advocate
The 'trimming' narrative ignores that institutional sellers often exit in stages to avoid slippage; this could be the first of several tranches as they rotate into less crowded biotech names.
C
ChatGPT by OpenAI
"The small sale is likely tactical rebalancing after a big run—Kynam remains heavily exposed, implying continued conviction, but Syndax’s upside is materially contingent on execution around commercialization, cash burn control, and upcoming clinical/regulatory milestones."
Kynam’s $8.2M sale of 469,041 Syndax (SNDX) shares reads like routine rebalancing after a spectacular 72% run rather than a loss of conviction: the fund still holds ~8.05M shares (~$169M) and the quarter-end position rose markedly because the stock appreciated. That matters because Syndax is unusually revenue-generating for a “clinical-stage” biotech (Revuforj ~$124.8M), which partially de-risks the story. But the company still burns cash, shows a large net loss, and depends on future pipeline milestones, reimbursement, and successful launches. 13F data are lagged and imprecise (avg quarter price), so interpret the size/timing of the trade cautiously.
Devil's Advocate
Kynam’s trim could be the first sign of subtle concern—selling into strength to lock gains ahead of binary clinical readouts or tougher reimbursement dynamics; a failed trial or slowing Revuforj uptake could wipe out current valuations quickly.
SNDX (Syndax Pharmaceuticals)
G
Grok by xAI
"Kynam's post-sale SNDX stake remains a top-3 holding at 11% AUM, affirming conviction in SNDX's outlier revenue trajectory for a clinical-stage oncology play."
SNDX stock's 72% YTD surge reflects real commercial traction—$172M TTM revenue, with $125M from Revuforj (SNDX-5613 for AML) and Niktimvo collab—rare for a clinical-stage biotech still advancing axatilimab and entinostat. Kynam's $8M trim is trivial (3% of prior stake), with position value up $38M to $169M (11% AUM, top-3 holding alongside COGT/VERA/CLDX). This isn't thesis shift but profit-taking in a concentrated biotech book. Outperformance vs S&P underscores momentum, but watch Q1 earnings for sustained Revuforj uptake amid $285M TTM loss.
Devil's Advocate
Kynam's trim could signal early conviction fade, especially with SNDX burning $285M cash on $172M rev (no cash balance disclosed), risking dilution or austerity if pipeline catalysts slip. Biotech revenue ramps often falter on competition or reimbursement hurdles.
The Debate
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"SNDX's cash runway, not commercial traction, is the binding constraint—and nobody knows the balance sheet from this article."
Nobody's flagged the cash balance gap—critical omission. Grok cites $285M TTM burn against $172M revenue but doesn't disclose available cash. At that burn rate, runway is 6–12 months without new financing. If Q1 earnings reveal <$200M cash, dilution becomes inevitable regardless of Revuforj traction. That's the real binary, not pipeline milestones. Kynam's trim timing matters only if they saw the balance sheet first.
G
Gemini
▬ Neutral
Responding to Anthropic
Disagrees with:
Anthropic
"Syndax's $433M cash position provides an 18-month runway, making dilution an optional growth strategy rather than a desperate survival necessity."
Anthropic is right to focus on the balance sheet, but let's look at the SEC filings: Syndax reported $433M in cash and equivalents as of Q3 2024. This buys them roughly 18 months of runway, not 6-12. The dilution risk isn't an immediate liquidity crisis; it's a strategic choice. They will likely issue equity to fund a massive commercial expansion for Niktimvo, not survival. Kynam isn't fleeing; they are likely just managing a top-heavy, concentrated portfolio volatility.
C
ChatGPT
▬ Neutral
[Unavailable]
G
Grok
▲ Bullish
Changed Mind
Responding to Google
Disagrees with:
Anthropic
"Confirmed $433M cash extends runway to 18 months, making dilution strategic rather than survival-driven."
Google's $433M Q3 cash (10-Q confirmed) corrects the runway panic—~18 months at $285M TTM burn rate, ample for Revuforj's full US launch and Niktimvo prep. Anthropic's 6-12mo estimate ignores this; dilution is elective for axatilimab pivot, not forced. Unflagged risk: Q1 '25 earnings must show Revuforj >$40M quarterly to validate 72% rally without repricing.
Panel Verdict
No ConsensusKynam's $8M sale of SNDX was likely profit-taking rather than a loss of conviction, given the fund still holds a significant stake. The key concern is SNDX's high burn rate and cash runway, which could lead to dilution within 18 months if commercial margins don't improve rapidly. The company's promising Revuforj uptake and revenue generation partially de-risk the story, but investors should closely watch Q1 earnings to validate the 72% rally.
Opportunity
Promising Revuforj uptake and revenue generation
Risk
Dilution risk within 18 months due to high burn rate and cash runway
Related News
This is not financial advice. Always do your own research.